Access cutting-edge ovarian cancer treatment through this clinical trial at a research site in Seattle. Study-provided care at no cost to qualified participants.
Access ovarian cancer specialists in Seattle at no cost
This study follows strict safety protocols and ethical guidelines
All study-related ovarian cancer treatment provided free
The purpose of this study is to evaluate the optimal dose of 2X-121 as single agent therapy at 600 mg daily (split BID 200 mg morning + 400 mg evening) compared to 800 mg daily (split BID 400 mg morning + 400 mg evening) in recurrent, advanced ovarian cancer patients that have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible. The optimal dose will be selected based on an integrated analysis of PK/PD,
Sponsor: Allarity Therapeutics
Check if you qualify for this ovarian cancer clinical trial in Seattle, WA
If you're searching for ovarian cancer treatment options in Seattle, WA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Seattle research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ovarian cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.